GURUFOCUS.COM » STOCK LIST » Latin America » Argentina » BUE » Biogen Inc (BUE:BIIB) » Definitions » Total Long-Term Liabilities
Switch to:

Biogen (BUE:BIIB) Total Long-Term Liabilities

: ARS1,540,199 Mil (As of Mar. 2023)
View and export this data going back to 2019. Start your Free Trial

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Biogen's Total Long-Term Liabilities for the quarter that ended in Mar. 2023 was ARS1,540,199 Mil.


Biogen Total Long-Term Liabilities Historical Data

The historical data trend for Biogen's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Long-Term Liabilities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 337,916.00 539,839.29 829,311.00 870,473.19 1,323,244.65

Biogen Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Total Long-Term Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 906,982.48 986,706.01 1,133,970.93 1,323,244.65 1,540,198.61

Biogen Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.


Biogen Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Biogen's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Biogen logo
Industry
Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Biogen (BUE:BIIB) Headlines